American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Gut microbiome composition is associated with engraftment syndrome in multiple myeloma patients undergoing autologous stem cell transplantation
    Meeting Abstract

    Feinman, R.; Aptekmann, A. A.; Colorado, I.; Roy, S.; Zenreich, J.; Dar, S. H.; Aleman, A.; Unawane, R.; Zhuang, M.; Korkoleo, M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A 3-year follow-up comparison of clinical outcomes from Zuma-5 (axicabtagene ciloleucel) and the international scholar-5 external control cohort in relapsed/refractory follicular lymphoma (R/R FL)
    Meeting Abstract

    Ghione, P.; Palomba, M. L.; Ray, M. D.; Limbrick-Oldfield, E. H.; Owen, J.; Kanters, S.; Bobillo, S.; Ribeiro, M. T.; Jacobson, C. A.; Neelapu, S. S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Tracking immune reconstitution in the bone marrow following allogeneic hematopoietic transplantation in humans reveals early dominance of innate lymphoid populations
    Meeting Abstract

    DeWolf, S.; Kuttiyara, J.; Vinci, P.; Slingerland, J.; Marcello, L. T.; Giardina, P. A.; Donohoe, W.; Lin, R. J.; Papadopoulos, E. B.; Gyurkocza, B.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Outcomes and management of SARS-CoV2 omicron variant in recipients of hematopoietic cell transplantation (HCT) and CAR-T therapy
    Meeting Abstract

    Infante, M. S.; DeWolf, S.; Tamari, R.; Dahi, P. B.; Lee, Y. J.; Politikos, I.; Barker, J. N.; Babady, N. E.; Ramanathan, L.; Seo, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Peripheral blast count at apheresis acts independent of disease burden as a risk factor for survival following tisagenlecleucel in children and young adults
    Meeting Abstract

    Fabrizio, V. A.; Miller, K.; Baggott, C.; Prabhu, S.; Pacenta, H.; Phillips, C. L.; Rossoff, J.; Stefanski, H. E.; Talano, J.; Moskop, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Predictors and implications of renal injury in large cell lymphoma patients receiving CD19 CAR T cell therapy
    Meeting Abstract

    Boardman, A. P.; Gutgarts, V.; Flynn, J. R.; Devlin, S. M.; Tomas, A. A.; Fein, J. A.; Slingerland, J.; Parascondola, A.; Lin, R. J.; Scordo, M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy outcomes and characteristics of patients with multiple myeloma (MM) who achieved sustained minimal residual disease negativity after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1
    Meeting Abstract

    Munshi, N. C.; Paiva, B.; Martin, T.; Usmani, S.; Lin, Y.; Schecter, J. M.; Jackson, C. C.; Madduri, D.; Zudaire, E.; Yeh, T. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Interim phase I clinical data of FT819-101, a study of the first-ever, off-the-shelf, iPSC-derived TCR-less CD19 CAR T-cell therapy for patients with relapsed/refractory B-cell malignancies
    Meeting Abstract

    Mehta, A.; Farooq, U.; Chen, A.; McGuirk, J. P.; Ly, T.; Wong, L.; Cooley, S.; Valamehr, B.; Elstrom, R.; Chu, Y. W.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Universal updated phase 1 data highlights role of allogeneic anti-BCMA ALLO-715 therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Matous, J. V.; Liedtke, M.; Sidana, S.; Oluwole, O. O.; Mohan, M.; Cruz, J. C.; Nath, R.; Anwer, F.; Rossi, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Prognostic impact of comorbidities on outcomes of patients (pts) with relapsed or refractory large B-cell lymphoma (r/r LBCL) treated with chimeric antigen receptor T-cell therapy (CART)
    Meeting Abstract

    Greenbaum, U.; Hashmi, H.; Elsawy, M.; Kim, S.; Moskop, A.; Awan, F. T.; Farooq, U.; Ganguly, S.; Hematti, P.; Jain, M. D.; more...
    Blood (2022)

    Fulltext@MSK | Save